136 related articles for article (PubMed ID: 17417662)
1. New clinical grading system for chronic GVHD predicts duration of systemic immunosuppressive treatment and GVHD-specific and overall survival.
Kim ST; Jung CW; Lee J; Kwon JM; Oh SY; Park BB; Lee HR; Kim HJ; Kim K; Kim WS; Ahn JS; Kang WK; Park K
Bone Marrow Transplant; 2007 Jun; 39(11):711-6. PubMed ID: 17417662
[TBL] [Abstract][Full Text] [Related]
2. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset.
Sohn SK; Kim DH; Kim JG; Lee NY; Suh JS; Lee KS; Lee KB
Bone Marrow Transplant; 2004 Jul; 34(1):63-8. PubMed ID: 15133486
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
[TBL] [Abstract][Full Text] [Related]
4. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
5. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation.
Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH
Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588
[TBL] [Abstract][Full Text] [Related]
6. Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT; Nelson RP; Schwartz JE; Mirowski GW; Billings SD
Am J Dermatopathol; 2007 Feb; 29(1):1-6. PubMed ID: 17284954
[TBL] [Abstract][Full Text] [Related]
7. Histologic features of the liver biopsy predict the clinical outcome for patients with graft-versus-host disease of the liver.
Duarte RF; Delgado J; Shaw BE; Wrench DJ; Ethell M; Patch D; Dhillon AP; Mackinnon S; Potter MN; Quaglia AF
Biol Blood Marrow Transplant; 2005 Oct; 11(10):805-13. PubMed ID: 16182181
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation.
Lee JH; Lee JH; Choi SJ; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Lee KH
Br J Haematol; 2003 Aug; 122(4):637-44. PubMed ID: 12899719
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD.
Kim DH; Sohn SK; Jeon SB; Baek JH; Kim JG; Lee NY; Suh JS; Lee KB; Shin IH
Bone Marrow Transplant; 2006 Jan; 37(1):101-8. PubMed ID: 16258533
[TBL] [Abstract][Full Text] [Related]
10. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
11. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
12. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
15. Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades.
Svahn BM; Ringdén O; Remberger M
Transplantation; 2006 Jun; 81(11):1600-3. PubMed ID: 16770251
[TBL] [Abstract][Full Text] [Related]
16. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
17. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
18. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
Yamada MF; Miyamura K; Fujiwara T; Kohata K; Okitsu Y; Ohguchi H; Yamamoto J; Yokoyama H; Tomiya Y; Ishizawa K; Kameoka J; Harigae H
Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456
[TBL] [Abstract][Full Text] [Related]
19. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
[TBL] [Abstract][Full Text] [Related]
20. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
